Grifols (GRFS) said Tuesday it received a $21 million grant from the Michael J. Fox Foundation for Parkinson's Research to identify biomarkers that can potentially indicate the likelihood of Parkinson's disease before clinical diagnosis.
Proceeds from the grant will be used for a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years and track the evolution of distinct plasma proteins in patients with Parkinson's disease, according to the company.
The grant is part of the Chronos-PD initiative, which focuses on the discovery of new diagnostic tools and novel treatments, Grifols added.
Price: 7.15, Change: -0.08, Percent Change: -1.11
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。